OneMedNet Signs Strategic Data Licensing Agreement with Risorius
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy ONMD?
OneMedNet Corporation announced a strategic data licensing agreement with Risorius. This new relationship supports OneMedNet's continued focus on expanding its base of subscription contracts, adding multi-year agreements that represent millions of dollars in incremental recurring revenue. Under the agreement, Risorius has licensed access to large-scale electroencephalography and polysomnography waveform data paired with clinically meaningful context and longitudinal follow-up. The datasets will support internal R&D, model development, and validation efforts, including the advancement of EEG-based digital biomarkers and an AI Co-Scientist platform designed to support neurological and psychiatric clinical studies, especially for pharmaceutical companies and academic hospitals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONMD
About ONMD
OneMedNet Corporation is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (RWD), through its OneMedNet iRWD solution. The Company provides solutions within the clinical image archives of healthcare providers. It de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with technology and in-house clinical expertise, the Company meets the rigorous RWD life science requirements. OneMedNet iRWD offers advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data are indexed at each network site using artificial intelligence (AI)/ machine learning (ML) technology. This includes EHR, radiology, cardiology, lab, path, and others. In addition to its customized data packages, it also offers regulatory-grade, pre-packaged imaging RWD sets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OneMedNet Shares Decline Amid RWD Platform Growth Strategy Validation
- Stock Volatility: OneMedNet (NASDAQ:ONMD) shares fell 26.55% on Monday, reflecting market concerns over short-term performance despite the long-term growth potential of its RWD platform.
- Growth Strategy: The company is actively converting customer evaluations into commercial subscriptions, which are expected to drive predictable growth and millions in annual recurring revenue (ARR), indicating the sustainability of its business model.
- Platform Integration: OneMedNet has integrated over 2,130 healthcare sites into its iRWD platform powered by Palantir Technologies, accelerating adoption among life sciences and AI health innovators while providing near-real-time access to integrated clinical and longitudinal datasets.
- Customer Benefits: Life sciences teams and researchers will gain access to comprehensive regulatory-grade multimodal real-world data, with AI-driven search tools enhancing innovation and reducing trial risks, thereby improving research efficiency and evidence generation capabilities.
See More
OneMedNet Launches Next Phase of Commercial Rollout
- Platform Launch Progress: OneMedNet announced the next phase of its Real-World Data platform's commercial rollout, powered by Palantir's Foundry technology, leading to an 81.46% surge in stock price, reflecting strong market confidence in its product.
- Positive Customer Feedback: CEO Aaron Green noted that customer feedback has reinforced the platform's performance, speed, and depth of discovery, which is expected to drive subscription growth, resulting in predictable revenue increases and millions in annual recurring revenue.
- Data Integration Advantage: With over 2,130 healthcare sites integrated into its iRWD platform, OneMedNet provides real-time access to comprehensive regulatory-grade multimodal data, aiming to accelerate adoption among life sciences and AI health innovators, enhancing customer workflow efficiency.
- Market Environment Analysis: Despite a weak overall market, OneMedNet's positive news resonates within the healthcare sector, indicating the company's strategic position in the healthcare data landscape, even as its stock remains below its 20-day and 100-day simple moving averages.
See More
U.S. Stocks Drop Over 600 Points in Morning Trading
- Market Decline: U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Friday, a 1.25% drop to 48,879.67, indicating weakened market sentiment.
- Tech Sector Drop: Information technology stocks fell by 1.8% during Friday's trading, reflecting investor concerns about the sector's outlook, which may impact future investment decisions.
- Producer Prices Rise: U.S. producer prices increased by 0.5% month-over-month in January, surpassing market expectations of 0.3% and the revised 0.4% gain in December, indicating persistent inflationary pressures that could influence Federal Reserve policy.
- Commodity Market Fluctuations: Oil prices rose by 3.5% to $67.51, while gold increased by 1% to $5,243.90, suggesting that investors are turning to commodities for safety amid an uncertain stock market environment.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
See More
OneMedNet (ONMD) Aids mlHealth in FDA Approval of AI BrainCT Software
- FDA Approval Milestone: OneMedNet partnered with mlHealth 360 to secure FDA clearance for Scaida BrainCT-ICH, an AI software that detects intracranial hemorrhage from head CT scans in approximately 5.97 seconds, significantly enhancing clinical decision-making in acute care.
- Critical Data Support: OneMedNet's regulatory-grade Real-World Data, encompassing electronic medical records, diagnostic imaging, and clinical reports, played a pivotal role in model development, validation, and regulatory submission, underscoring the importance of high-quality data in accelerating innovation.
- Market Performance Review: Over the past year, ONMD's stock traded between $0.30 and $4.22, with a nearly 7% increase to $0.92, reflecting market recognition of its innovative capabilities.
- CEO Insights: OneMedNet's CEO Aaron Green stated that seeing the company's Real-World Data directly contribute to an FDA-cleared solution reinforces the value of high-quality data in driving meaningful innovation.
See More
OneMedNet Shares Decline Amid RWD Platform Growth Strategy Validation
- Stock Volatility: OneMedNet (NASDAQ:ONMD) shares fell 26.55% on Monday, reflecting market concerns over short-term performance despite the long-term growth potential of its RWD platform.
- Growth Strategy: The company is actively converting customer evaluations into commercial subscriptions, which are expected to drive predictable growth and millions in annual recurring revenue (ARR), indicating the sustainability of its business model.
- Platform Integration: OneMedNet has integrated over 2,130 healthcare sites into its iRWD platform powered by Palantir Technologies, accelerating adoption among life sciences and AI health innovators while providing near-real-time access to integrated clinical and longitudinal datasets.
- Customer Benefits: Life sciences teams and researchers will gain access to comprehensive regulatory-grade multimodal real-world data, with AI-driven search tools enhancing innovation and reducing trial risks, thereby improving research efficiency and evidence generation capabilities.
See More
OneMedNet Launches Next Phase of Commercial Rollout
- Platform Launch Progress: OneMedNet announced the next phase of its Real-World Data platform's commercial rollout, powered by Palantir's Foundry technology, leading to an 81.46% surge in stock price, reflecting strong market confidence in its product.
- Positive Customer Feedback: CEO Aaron Green noted that customer feedback has reinforced the platform's performance, speed, and depth of discovery, which is expected to drive subscription growth, resulting in predictable revenue increases and millions in annual recurring revenue.
- Data Integration Advantage: With over 2,130 healthcare sites integrated into its iRWD platform, OneMedNet provides real-time access to comprehensive regulatory-grade multimodal data, aiming to accelerate adoption among life sciences and AI health innovators, enhancing customer workflow efficiency.
- Market Environment Analysis: Despite a weak overall market, OneMedNet's positive news resonates within the healthcare sector, indicating the company's strategic position in the healthcare data landscape, even as its stock remains below its 20-day and 100-day simple moving averages.
See More
U.S. Stocks Drop Over 600 Points in Morning Trading
- Market Decline: U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Friday, a 1.25% drop to 48,879.67, indicating weakened market sentiment.
- Tech Sector Drop: Information technology stocks fell by 1.8% during Friday's trading, reflecting investor concerns about the sector's outlook, which may impact future investment decisions.
- Producer Prices Rise: U.S. producer prices increased by 0.5% month-over-month in January, surpassing market expectations of 0.3% and the revised 0.4% gain in December, indicating persistent inflationary pressures that could influence Federal Reserve policy.
- Commodity Market Fluctuations: Oil prices rose by 3.5% to $67.51, while gold increased by 1% to $5,243.90, suggesting that investors are turning to commodities for safety amid an uncertain stock market environment.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
See More
OneMedNet (ONMD) Aids mlHealth in FDA Approval of AI BrainCT Software
- FDA Approval Milestone: OneMedNet partnered with mlHealth 360 to secure FDA clearance for Scaida BrainCT-ICH, an AI software that detects intracranial hemorrhage from head CT scans in approximately 5.97 seconds, significantly enhancing clinical decision-making in acute care.
- Critical Data Support: OneMedNet's regulatory-grade Real-World Data, encompassing electronic medical records, diagnostic imaging, and clinical reports, played a pivotal role in model development, validation, and regulatory submission, underscoring the importance of high-quality data in accelerating innovation.
- Market Performance Review: Over the past year, ONMD's stock traded between $0.30 and $4.22, with a nearly 7% increase to $0.92, reflecting market recognition of its innovative capabilities.
- CEO Insights: OneMedNet's CEO Aaron Green stated that seeing the company's Real-World Data directly contribute to an FDA-cleared solution reinforces the value of high-quality data in driving meaningful innovation.
See More
